Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
IPO Year: 2015
Exchange: NASDAQ
Website: conformis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2021 | $2.50 → $2.00 | Outperform | Oppenheimer |
| 9/22/2021 | $3.00 → $2.50 | Outperform | Oppenheimer |
4 - Conformis Inc (0001305773) (Issuer)
4 - Conformis Inc (0001305773) (Issuer)
4 - Conformis Inc (0001305773) (Issuer)
4 - Conformis Inc (0001305773) (Issuer)
4 - Conformis Inc (0001305773) (Issuer)
4 - Conformis Inc (0001305773) (Issuer)
4 - Conformis Inc (0001305773) (Issuer)
4 - Conformis Inc (0001305773) (Issuer)
3 - Conformis Inc (0001305773) (Issuer)
4 - Conformis Inc (0001305773) (Issuer)
DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis' stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis' common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023. "We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body," said J. Kurt Jacobus, CEO o
BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), have each recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS and Glass Lewis share its be
BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best inte
BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary Total revenue of $13.0 million, a decrease of 15% year-over-year on a reported and constant currency basis.Product revenue of $12.5 million, a decrease of 17% year-over-year on a reported and constant currency basis.Conformis hip system revenue of $1.0 million, an increase of 30% year-over-year.Cash and cash equivalents of $26.2 million as of June 30, 2023.Announced merger agreement to be acquired by
NEW YORK, July 15, 2023 (GLOBE NEWSWIRE) -- Kaleyra, Inc. (NYSE:KLR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KLR to Tata Communications Limited for $7.25 per share in cash. If you are a KLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Conformis Inc. (NASDAQ:CFMS) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CFMS to Restor3d, Inc. for $2.27 per share in cash.
DURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ:CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approximate 96 percent premium to the closing price of Conformis stock on June 22, 2023. "This combination will create a leading personalized 3D-printed medical device company. Together, we share a common belief in the power of personalization. By leveraging the strengths in our respective portfolios around art
BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023. Three months ended March 31,
BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time
BILLERICA, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, recently launched a patient education and awareness campaign in selected U.S. markets to strengthen the importance of patient choice by highlighting the differences between traditional "off-the-shelf" products and truly personalized knee systems that offer clinically proven benefits to patients. The campaign is currently airing in the Boston, MA and Minneapolis-St. Paul, MN metro areas in an effort to educate future patients about their options when it comes to total knee replacement surgery. Independent surveys
BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur
SC 13G/A - Conformis Inc (0001305773) (Subject)
SC 13G/A - Conformis Inc (0001305773) (Subject)
SC 13G/A - Conformis Inc (0001305773) (Subject)
SC 13G - Conformis Inc (0001305773) (Subject)
SC 13G/A - Conformis Inc (0001305773) (Subject)
SC 13G - Conformis Inc (0001305773) (Subject)
SC 13G/A - Conformis Inc (0001305773) (Subject)
SC 13G - Conformis Inc (0001305773) (Subject)
SC 13G - Conformis Inc (0001305773) (Subject)
SC 13G/A - Conformis Inc (0001305773) (Subject)
15-12G - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
S-8 POS - Conformis Inc (0001305773) (Filer)
Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.00 from $2.50 previously
Oppenheimer reiterated coverage of Conformis with a rating of Outperform and set a new price target of $2.50 from $3.00 previously
BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Operating Officer. Mike brings to this role 30 years of experience in manufacturing and operations with a strong focus in precision metal products, medical devices, continuous improvement, and strategic business planning," said Mark Augusti, President and Chief Executive officer. "I look forward to the contributions he will make as a member of the Conformis team." Michael Fillion Prior to joining Conformis, Michael served as the Executive Vice Pr
BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong public company experience and leadership capabilities will help support our growth strategy and further strengthens our executive team," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions she will make as a member of the Conformis team." Denise Pedulla Prior to joining Conformis, Denise served as the General Counsel and Corporate Secreta
BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.P. of U.S. Marketing. As we continue to advance our growth strategy, we are confident that James' extensive background in new product introductions and multi-channel marketing will help to strengthen Conformis brand recognition and position us to capitalize on anticipated growth in the ambulatory surgery center space," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions James will make as a member of Confo
BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023. Three months ended March 31,
BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time
BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur
BILLERICA, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, provided today a business update and reported preliminary financial results for the fourth quarter and year ended December 31, 2022. Executive Commentary – Mark Augusti, President and CEO "Today we are announcing the launch of our new advertising campaign highlighting our Image-to-Implant Platinum Services program. This campaign focuses on highlighting the benefits of a fully personalized knee to patients and will launch initially in a select number of targeted markets. We are also providing an update of our
BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in
BILLERICA, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Summary Total revenue of $13.8 million, a decrease of 3% year-over-year on a reported basis and 2% on a constant currency basis.Product revenue of $13.6 million, a decrease of 3% year-over-year on a reported basis and 2% on a constant currency basis.Conformis hip system revenue of $0.6 million, a decrease of 19% year-over-year.Cash and cash equivalents of $59.6 million as of September 30, 2022. Executive Comm
BILLERICA, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Wednesday, November 2, 2022. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call later that day at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial
BILLERICA, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Summary Total revenue of $15.3 million. Total revenue in the second quarter of 2021 included significant non-recurring royalty revenue.Product revenue of $15.1 million, remained flat year-over-year on a reported basis and increased 1% on a constant currency basis.Conformis hip system revenue of $0.7 million, a decrease of 18% year-over-year.Cash and cash equivalents of $72.6 million as of June 30, 2022. Ex
BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the market closes on Monday, August 8, 2022. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call the next day before the market opens on Tuesday, August 9, 2022, at 8:30 a.m. Eastern Time to discuss the financial results and to provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephon
BILLERICA, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2022. First Quarter 2022 Summary Total revenue of $15.6 million, an increase of 12% year-over-year on a reported basis and 13% on a constant currency basis.Product revenue of $14.9 million, an increase of 9% year-over-year on a reported and constant currency basis.Conformis hip system revenue up 18% year-over-year to $0.8 million.Cash and cash equivalents of $82.7 million as of March 31, 2022.Recently completed the 250th Imprint procedure